TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07287397: Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Sponsor: Vector Y Therapeutics · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 36 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,926,100

Rescue Site Savings

+$1,269,475

Unlock Full NCT07287397 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07287397 Rescue Dossier →